Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
Globe Newswire•02/11/2026•08:00 ET
0
Key Highlights
- ➤Cellectar (CLRB) will report third-quarter financial results November 10, 2026
- ➤Cellectar will provide a corporate update during its November 10 conference call
- ➤Iopofosine I 131 has been tested in Phase 2b trials across three cancer indications
- ➤CLR 125 is in a Phase 1b TNBC study to determine the subsequent Phase 2 dose
FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2026, and provide a corporate update on November 10, 2026, at 8:30 a.m. Eastern Time.
Conference Call & Webcast Details: Date: Tuesday, November 10, 2026 Time: 8:30 am Eastern Time Toll Free: 1-800-717-1738 Conference ID: Webcast: 29257 Click HERE
Get started
Create a free account to read the full story.